The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - BMS GmbH & Co. KG; Eisai; Roche
Speakers' Bureau - AstraZeneca; BMS GmbH & Co. KG; SERVIER
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Lilly
Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
 
Kohei Shitara
Honoraria - Bristol-Myers Squibb; Janssen; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Florian Lordick
Honoraria - Art Tempi; AstraZeneca; BioNTech; Bristol-Myers Squibb; Elsevier; Incyte; Lilly; Medscape; Medupdate; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER; Streamedup!
Consulting or Advisory Role - Amgen; Astellas Pharma; Beigene; Bristol-Myers Squibb; Daichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; SERVIER; Zymeworks
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly
 
Yung-Jue Bang
Consulting or Advisory Role - Alexo Therapeutics; Amgen; Astellas Pharma; Daewoong Pharmaceutical; Hanmi; Samyang
 
Peter C. Enzinger
Consulting or Advisory Role - ALX Oncology; Arcus Biosciences; Astellas Pharma; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Celgene; Chimeric Therapeutics; Coherus Biosciences; Daiichi Sankyo; Five Prime Therapeutics; IDEAYA Biosciences; Istari; Legend Biotech; Lilly; loxo; Merck; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Turning Point Therapeutics; Xencor; Zymeworks
 
David H. Ilson
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly/ImClone; Macrogenics; Merck; Roche/Genentech; Taiho Pharmaceutical
 
Manish A. Shah
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Oncolys BioPharma (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; ALX Oncology; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Taiho Pharmaceutical; Takeda; TERUMO; Zymeworks
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Rui-hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; HenRui; Junshi Biosciences; KYM Biosciences; Merck Serono; Roche
 
Giuseppe Aprile
Consulting or Advisory Role - Amgen; Baxter; Bristol-Myers Squibb/Celgene; Lilly; Merck; MSD; MSD; SERVIER
 
Jianming Xu
No Relationships to Disclose
 
Joseph Chao
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Coherus Biosciences; Daiichi Sankyo; Foundation Medicine; Geneos; Guardant Health; Lilly; Merck; Novartis; Roche; Silverback Therapeutics; Turning Point Therapeutics
Speakers' Bureau - Bristol Myers Squibb; Merck
Research Funding - Brooklyn Immunotherapeutics (Inst); Merck (Inst); Novonco Therapeutics (Inst)
Travel, Accommodations, Expenses - Amgen; Macrogenics
Other Relationship - Yiviva
 
Roberto Pazo-Cid
No Relationships to Disclose
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Blueprint Medicines; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks
 
Jianning Yang
Employment - Abbvie (I); Astellas Pharma
Stock and Other Ownership Interests - Abbvie (I)
 
Diarmuid Martin Moran
Employment - Astellas Pharma
 
Pranob P. Bhattacharya
Employment - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Ahsan Arozullah
Employment - Astellas Pharma
 
Jung Wook Park
Employment - Astellas Amgen BioPharama
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; Amgen; Arcus Biosciences; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Insys Therapeutics; Merck; Novartis; SERVIER; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly